For more than sixty years, MIMS Group has been a quiet but essential presence in the lives of healthcare professionals across Asia-Pacific — a trusted keeper of medicines knowledge at the moment of clinical decision. Now, under new leadership, the company is asking a deeper question: what does that trust become when it is rebuilt for a digital world? The launch of MIMS Pulse and the expansion of eMIMS Plus signal not merely a product release, but a deliberate reckoning with how accumulated institutional knowledge transforms into living, scalable technology.
MIMS Transforms Medical Data Into AI-Powered Clinical Platforms
Transforming trusted medical data into the next generation of digital products
Mark
So MIMS has been around since 1963—that's a long track record in medicines information. What's actually changing now?
Mimi
The core asset hasn't changed—they have trusted medical data and deep relationships with healthcare professionals across Asia. But the delivery mechanism is being rebuilt. Instead of just publishing information, they're building platforms like MIMS Pulse that integrate into clinical workflows, and they're expanding geographically and into new services.
Luke
Right, but I want to be careful here. The announcement says MIMS Pulse combines medicines data with modern technology, but it doesn't specify what that technology is or how it's different from what competitors offer. We know it exists and was launched, but we don't have independent verification of its capabilities.
Mark
Fair point. What about the geographic expansion—is that actually happening or is it planned?
Mimi
eMIMS Plus is already live in India and Malaysia. That's concrete. The Southeast Asia expansion and new clinical modules are described as plans, so those are still ahead.
Luke
And the US and UK medical communications operations—are those new offices or existing ones being expanded? The announcement doesn't say when they were established or how many people work there.
Mark
So we know the company is moving, but some of the details about scale and timeline are still vague.
Mimi
Exactly. What we can confirm is that there's a new CEO, a reorganization happened, and specific products have launched or expanded into named markets. The ambition to go global is clear from leadership, but the execution details are still unfolding.
Luke
And the AI angle—the announcement mentions AI-enabled content capabilities, but doesn't explain what that means operationally or how it's being used. That's worth noting as a gap.
Mark
So the story is real, but we're seeing the announcement of direction more than proof of arrival.
Mimi
That's the right way to read it. This is a company signaling a transformation and showing early evidence of it, not a company that's already transformed.
O Pulso
- A company defined by print and portals for six decades is now racing to reinvent itself as a platform business before the digital health landscape consolidates around competitors.
- New CEO Sohil Goswami, just months into his tenure, has already reorganized leadership and launched MIMS Pulse — a clinical decision support platform designed to embed trusted medicines data directly into the workflow of care.
- eMIMS Plus, already proven in Australia, is pushing into India and Malaysia with Southeast Asia next, while a dental-focused offshoot called Drugs4Dent signals ambitions beyond the company's traditional boundaries.
- The Medical Communications division is planting commercial flags in the US and UK, betting that AI-enabled content and intelligence-led services can win global life sciences clients far from MIMS' home markets.
- With over two million healthcare professional subscribers across 17 markets, the company is not starting from scratch — it is attempting the harder task of transforming deep-rooted relationships into next-generation digital scale.
For more than sixty years, MIMS Group has been a quiet but essential presence in the lives of healthcare professionals across Asia-Pacific — a trusted keeper of medicines knowledge at the moment of clinical decision. Now, under new leadership, the company is asking a deeper question: what does that trust become when it is rebuilt for a digital world? The launch of MIMS Pulse and the expansion of eMIMS Plus signal not merely a product release, but a deliberate reckoning with how accumulated institutional knowledge transforms into living, scalable technology.
MIMS Group, the Asia-Pacific healthcare technology company that has supplied medicines information to clinicians since 1963, is undergoing its most significant transformation in decades. The shift accelerated in January 2026 when Sohil Goswami became Group CEO and moved quickly to reorganize the business around a platform-driven future.
At the center of that future is MIMS Pulse, a newly launched clinical decision support platform that takes the company's foundational asset — decades of trusted medicines data and clinical knowledge — and rebuilds it for modern healthcare environments. Designed to integrate into existing clinical workflows, Pulse aims to help healthcare professionals make safer, faster decisions at the point of care. Alongside it, eMIMS Plus, a digital medicines information platform Goswami helped establish in Australia, has expanded to India and Malaysia, with a Southeast Asia rollout planned and a dental-care service, Drugs4Dent, in development.
Goswami has described the company's direction as an act of translation — preserving what healthcare professionals have long relied upon while rebuilding it for a digital-first world. That translation extends to MIMS' Medical Communications division, which is opening commercial operations in the United States and United Kingdom to serve global life sciences organizations. The division is investing in AI-enabled content, digital events, and what the company calls intelligence-led services: data-informed offerings that help healthcare and life sciences clients understand markets, engage professionals, and make better decisions.
MIMS operates across 17 markets and serves more than two million healthcare professional subscribers through its drug information portal, digital publications, and print products. Headquartered in Singapore, the company has offices spanning from Australia to Vietnam to the UAE. The moves underway represent a deliberate effort to carry sixty years of institutional trust into a new era of scalable, technology-enabled platforms — and to compete for that future on a genuinely global stage.
MIMS Group, an Asia-Pacific healthcare technology company built on six decades of medicines information, is reshaping itself into a platform-driven business. The transformation accelerated this year under new Group CEO Sohil Goswami, who took the helm in January 2026 and has since reorganized the company's businesses and leadership to position it for what executives describe as the next phase of growth.
The centerpiece of this shift is MIMS Pulse, a clinical decision support platform launched recently that marries the company's historical strength—trusted medicines data and clinical knowledge—with modern technology infrastructure and flexible deployment options. The platform is designed to integrate into existing clinical workflows, helping healthcare professionals make safer and more efficient decisions at the point of care. Alongside it sits eMIMS Plus, a digital medicines information platform that began in Australia under Goswami's previous leadership of the clinical decision support business. eMIMS Plus has now expanded to India and Malaysia, with plans to roll out across Southeast Asia, add new clinical modules, and branch into dental care through a service called Drugs4Dent.
Goswami framed the company's pivot in terms of translation: taking what healthcare professionals have relied on for decades and rebuilding it for a digital-first world. "For decades, healthcare professionals have trusted MIMS' medicines information and expertise," he said. "Today, we are transforming that foundation into the next generation of digital products, platforms and services." The company is developing a global clinical decision support offering that will extend its data and technology capabilities into new markets and customer environments beyond its traditional Asia-Pacific stronghold.
The medical communications and marketing division is undergoing parallel expansion. MIMS' Medical Communications business, which handles clinical content and healthcare marketing, is establishing commercial operations in the United States and United Kingdom to reach new client segments and global life sciences organizations. The division is investing in digital events, AI-enabled content generation, and new models for engaging healthcare professionals and organizations. Beyond traditional information dissemination, MIMS is building what it calls "intelligence-led services"—offerings that help healthcare and life sciences companies understand their markets more deeply, connect with healthcare professionals more effectively, and make decisions informed by data and market insight.
The company operates across 17 markets globally and counts over two million healthcare professional subscribers to its drug information portal, digital publications, and print offerings. MIMS was established in 1963 and has grown into Asia's largest multi-channel provider of drug information, medical communications, events management, and healthcare recruitment services. Its headquarters are in Singapore, with offices spanning Australia, China, Germany, Hong Kong, Indonesia, India, Ireland, Japan, Korea, Malaysia, New Zealand, the Philippines, Taiwan, Thailand, the United Arab Emirates, and Vietnam.
Goswami's stated ambition is to build a MIMS that can compete and grow on a global scale while remaining relevant to the specific markets it serves. The company is consolidating its capabilities, strengthening its technology infrastructure, and creating new service models designed to leverage its established relationships within healthcare communities. The moves represent a deliberate effort to move beyond the information-and-communications model that defined MIMS for decades and toward technology-enabled platforms and services that can scale across geographies and customer types.
Citações Notáveis
For decades, healthcare professionals have trusted MIMS' medicines information and expertise. Today, we are transforming that foundation into the next generation of digital products, platforms and services.— Sohil Goswami, Group CEO
Quer a matéria completa?
Leia o original em USA Today ↗